$SSY
SUNLINK HEALTH SYSTEMS INC Stock $ssy

$ssy Overview Financials Valuation SEC Filings Company Website

2023 Q2 Form 10-Q Financial Statement

#000095017023020620 Filed on May 10, 2023

Income Statement

Concept	2023 Q2	2023 Q1	2022 Q1
Revenue	$10.99M	$11.53M	$10.53M
YoY Change	11.19%	9.56%	7.66%
Cost Of Revenue	$4.929M	$4.755M	$4.079M
YoY Change	16.03%	16.57%	10.78%
Gross Profit	$6.058M	$6.778M	$6.448M
YoY Change	7.54%	5.12%	5.77%
Gross Profit Margin	55.14%	58.77%	61.25%
Selling, General & Admin	$6.192M	$5.967M	$6.101M
YoY Change	-0.91%	-2.2%	18.79%
% of Gross Profit	102.21%	88.03%	94.62%
Research & Development
YoY Change
% of Gross Profit
Depreciation & Amortization	$596.0K	$414.0K	$384.0K
YoY Change	29.57%	7.81%	13.27%
% of Gross Profit	9.84%	6.11%	5.96%
Operating Expenses	$8.033M	$7.552M	$7.512M
YoY Change	2.41%	0.53%	13.2%
Operating Profit	-$1.975M	-$774.0K	-$1.064M
YoY Change	-10.67%	-27.26%	97.04%
Interest Expense	$74.00K	$41.00K	-$1.000K
YoY Change	2366.67%	-4200.0%	-85.71%
% of Operating Profit
Other Income/Expense, Net
YoY Change
Pretax Income	-$1.436M	-$733.0K	-$959.0K
YoY Change	-35.02%	-23.57%	79.25%
Income Tax	$0.00	-$6.000K	-$25.00K
% Of Pretax Income
Net Earnings	-$1.426M	-$762.0K	-$990.0K
YoY Change	-39.7%	-23.03%	86.44%
Net Earnings / Revenue	-12.98%	-6.61%	-9.4%
Basic Earnings Per Share		-$0.10	-$0.13
Diluted Earnings Per Share	-$0.20	-$0.11	-$142.4K
COMMON SHARES
Basic Shares Outstanding	7.032M	7.032M	6.954M
Diluted Shares Outstanding		7.032M	6.954M

Balance Sheet

Concept	2023 Q2	2023 Q1	2022 Q1
SHORT-TERM ASSETS
Cash & Short-Term Investments	$4.486M	$5.382M	$7.144M
YoY Change		-24.66%	-35.63%
Cash & Equivalents	$4.486M	$5.382M	$7.144M
Short-Term Investments
Other Short-Term Assets	$1.783M	$1.741M	$1.822M
YoY Change		-4.45%	-7.42%
Inventory	$1.754M	$1.787M	$1.919M
Prepaid Expenses
Receivables	$4.251M	$4.394M	$4.709M
Other Receivables	$0.00	$0.00	$3.586M
Total Short-Term Assets	$12.27M	$13.30M	$19.18M
YoY Change	-27.01%	-30.64%	-0.9%
LONG-TERM ASSETS
Property, Plant & Equipment	$8.281M	$8.394M	$9.145M
YoY Change	0.78%	-8.21%	31.11%
Goodwill
YoY Change
Intangibles	$1.180M	$1.182M
YoY Change	-1.75%
Long-Term Investments
YoY Change
Other Assets	$489.0K	$603.0K	$424.0K
YoY Change	-6.5%	42.22%	-17.67%
Total Long-Term Assets	$11.00M	$11.13M	$10.78M
YoY Change	-1.2%	3.24%	23.53%
TOTAL ASSETS
Total Short-Term Assets	$12.27M	$13.30M	$19.18M
Total Long-Term Assets	$11.00M	$11.13M	$10.78M
Total Assets	$23.27M	$24.43M	$29.96M
YoY Change	-16.73%	-18.45%	6.69%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$1.849M	$1.569M	$1.351M
YoY Change	37.27%	16.14%	-0.15%
Accrued Expenses	$2.986M	$2.615M	$5.582M
YoY Change		-53.15%	17.1%
Deferred Revenue
YoY Change
Short-Term Debt	$0.00	$0.00	$0.00
YoY Change
Long-Term Debt Due	$14.00K	$24.00K	$39.00K
YoY Change	-65.0%	-38.46%	-96.93%
Total Short-Term Liabilities	$4.869M	$4.677M	$7.493M
YoY Change	-36.69%	-37.58%	-16.27%
LONG-TERM LIABILITIES
Long-Term Debt	$0.00	$0.00	$25.00K
YoY Change	-100.0%	-100.0%	-98.79%
Other Long-Term Liabilities	$102.0K	$197.0K	$1.222M
YoY Change	-3.77%	-83.88%	636.14%
Total Long-Term Liabilities	$983.0K	$954.0K	$1.247M
YoY Change	-13.16%	-23.5%	-60.82%
TOTAL LIABILITIES
Total Short-Term Liabilities	$4.869M	$4.677M	$7.493M
Total Long-Term Liabilities	$983.0K	$954.0K	$1.247M
Total Liabilities	$5.852M	$5.631M	$8.740M
YoY Change	-33.67%	-35.57%	-27.96%
SHAREHOLDERS EQUITY
Retained Earnings	$3.005M	$4.431M
YoY Change	-37.4%
Common Stock	$14.26M	$14.26M
YoY Change	0.34%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity	$17.42M	$18.80M	$21.22M
YoY Change
Total Liabilities & Shareholders Equity	$23.27M	$24.43M	$29.96M
YoY Change	-16.73%	-18.45%	6.69%

Cashflow Statement

Concept	2023 Q2	2023 Q1	2022 Q1
OPERATING ACTIVITIES
Net Income	-$1.426M	-$762.0K	-$990.0K
YoY Change	-39.7%	-23.03%	86.44%
Depreciation, Depletion And Amortization	$596.0K	$414.0K	$384.0K
YoY Change	29.57%	7.81%	13.27%
Cash From Operating Activities	-$421.0K	$606.0K	-$244.0K
YoY Change		-348.36%	-248.78%
INVESTING ACTIVITIES
Capital Expenditures	$475.0K	$374.0K	$918.0K
YoY Change		-59.26%	207.02%
Acquisitions
YoY Change
Other Investing Activities	$11.00K	$0.00	$0.00
YoY Change
Cash From Investing Activities	-$464.0K	-$374.0K	-$918.0K
YoY Change		-59.26%	207.02%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities	-11.00K	-6.000K	-9.000K
YoY Change		-33.33%	12.5%
NET CHANGE
Cash From Operating Activities	-421.0K	606.0K	-244.0K
Cash From Investing Activities	-464.0K	-374.0K	-918.0K
Cash From Financing Activities	-11.00K	-6.000K	-9.000K
Net Change In Cash	-896.0K	226.0K	-1.171M
YoY Change		-119.3%	718.88%
FREE CASH FLOW
Cash From Operating Activities	-$421.0K	$606.0K	-$244.0K
Capital Expenditures	$475.0K	$374.0K	$918.0K
Free Cash Flow	-$896.0K	$232.0K	-$1.162M
YoY Change		-119.97%	760.74%

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value
CY2022Q2	us-gaap	Finance Lease Right Of Use Asset Statement Of Financial Position Extensible List FinanceLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList	http://fasb.org/us-gaap/2022#PropertyPlantAndEquipmentNet
	dei	Document Fiscal Period Focus DocumentFiscalPeriodFocus	Q3
	dei	Current Fiscal Year End Date CurrentFiscalYearEndDate	--06-30
CY2022Q2	us-gaap	Commitments And Contingencies CommitmentsAndContingencies
CY2023Q1	us-gaap	Commitments And Contingencies CommitmentsAndContingencies
	dei	Amendment Flag AmendmentFlag	false
	us-gaap	Defined Benefit Plan Type Extensible List DefinedBenefitPlanTypeExtensibleList	http://fasb.org/us-gaap/2022#PensionPlansDefinedBenefitMember
	us-gaap	Defined Benefit Plan Type Extensible List DefinedBenefitPlanTypeExtensibleList	http://fasb.org/us-gaap/2022#PensionPlansDefinedBenefitMember
CY2023Q1	us-gaap	Finance Lease Right Of Use Asset Statement Of Financial Position Extensible List FinanceLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList	http://fasb.org/us-gaap/2022#PropertyPlantAndEquipmentNet
CY2022Q2	us-gaap	Finance Lease Liability Current Statement Of Financial Position Extensible List FinanceLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList	http://fasb.org/us-gaap/2022#LongTermDebtCurrent
	dei	Document Fiscal Year Focus DocumentFiscalYearFocus	2023
	dei	Entity Central Index Key EntityCentralIndexKey	0000096793
CY2023Q1	us-gaap	Finance Lease Liability Current Statement Of Financial Position Extensible List FinanceLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList	http://fasb.org/us-gaap/2022#LongTermDebtCurrent
CY2022Q2	us-gaap	Finance Lease Liability Noncurrent Statement Of Financial Position Extensible List FinanceLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList	http://fasb.org/us-gaap/2022#LongTermDebtNoncurrent
CY2023Q1	us-gaap	Common Stock No Par Value CommonStockNoParValue
	us-gaap	Defined Benefit Plan Type Extensible List DefinedBenefitPlanTypeExtensibleList	http://fasb.org/us-gaap/2022#PensionPlansDefinedBenefitMember
CY2023Q1	us-gaap	Finance Lease Liability Noncurrent Statement Of Financial Position Extensible List FinanceLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList	http://fasb.org/us-gaap/2022#LongTermDebtNoncurrent
CY2022Q2	us-gaap	Common Stock No Par Value CommonStockNoParValue
	dei	Document Type DocumentType	10-Q
	dei	Document Quarterly Report DocumentQuarterlyReport	true
	dei	Document Period End Date DocumentPeriodEndDate	2023-03-31
	dei	Document Transition Report DocumentTransitionReport	false
	dei	Entity File Number EntityFileNumber	1-12607
	dei	Entity Registrant Name EntityRegistrantName	SUNLINK HEALTH SYSTEMS, INC.
	dei	Entity Incorporation State Country Code EntityIncorporationStateCountryCode	OH
	dei	Entity Tax Identification Number EntityTaxIdentificationNumber	31-0621189
	dei	Entity Address Address Line1 EntityAddressAddressLine1	900 Circle 75 Parkway
	dei	Entity Address Address Line2 EntityAddressAddressLine2	Suite 690
	dei	Entity Address City Or Town EntityAddressCityOrTown	Atlanta
	dei	Entity Address State Or Province EntityAddressStateOrProvince	GA
	dei	Entity Address Postal Zip Code EntityAddressPostalZipCode	30339
	dei	City Area Code CityAreaCode	770
	dei	Local Phone Number LocalPhoneNumber	933-7000
	dei	Entity Current Reporting Status EntityCurrentReportingStatus	Yes
	dei	Entity Interactive Data Current EntityInteractiveDataCurrent	Yes
	dei	Entity Filer Category EntityFilerCategory	Non-accelerated Filer
	dei	Entity Small Business EntitySmallBusiness	true
	dei	Entity Emerging Growth Company EntityEmergingGrowthCompany	false
	dei	Entity Shell Company EntityShellCompany	false
CY2023Q2	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	7031603
CY2023Q1	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	5382000
CY2022Q2	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	6794000
CY2023Q1	us-gaap	Receivables Net Current ReceivablesNetCurrent	4394000
CY2022Q2	us-gaap	Receivables Net Current ReceivablesNetCurrent	4624000
CY2023Q1	us-gaap	Inventory Net InventoryNet	1787000
CY2022Q2	us-gaap	Inventory Net InventoryNet	1748000
CY2023Q1	ssy	Employee Retention Credits Receivable Current EmployeeRetentionCreditsReceivableCurrent	0
CY2022Q2	ssy	Employee Retention Credits Receivable Current EmployeeRetentionCreditsReceivableCurrent	1761000
CY2023Q1	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	1741000
CY2022Q2	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	1888000
CY2023Q1	us-gaap	Assets Current AssetsCurrent	13304000
CY2022Q2	us-gaap	Assets Current AssetsCurrent	16815000
CY2023Q1	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	24549000
CY2022Q2	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	23920000
CY2023Q1	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	16155000
CY2022Q2	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	15703000
CY2023Q1	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	8394000
CY2022Q2	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	8217000
CY2023Q1	us-gaap	Intangible Assets Net Excluding Goodwill IntangibleAssetsNetExcludingGoodwill	1182000
CY2022Q2	us-gaap	Intangible Assets Net Excluding Goodwill IntangibleAssetsNetExcludingGoodwill	1201000
CY2023Q1	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	947000
CY2022Q2	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	1187000
CY2023Q1	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	603000
CY2022Q2	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	523000
CY2023Q1	us-gaap	Assets Noncurrent Other Than Noncurrent Investments And Property Plant And Equipment AssetsNoncurrentOtherThanNoncurrentInvestmentsAndPropertyPlantAndEquipment	2732000
CY2022Q2	us-gaap	Assets Noncurrent Other Than Noncurrent Investments And Property Plant And Equipment AssetsNoncurrentOtherThanNoncurrentInvestmentsAndPropertyPlantAndEquipment	2911000
CY2023Q1	us-gaap	Assets Assets	24430000
CY2022Q2	us-gaap	Assets Assets	27943000
CY2023Q1	us-gaap	Accounts Payable Current AccountsPayableCurrent	1569000
CY2022Q2	us-gaap	Accounts Payable Current AccountsPayableCurrent	1347000
CY2023Q1	us-gaap	Long Term Debt Current LongTermDebtCurrent	24000
CY2022Q2	us-gaap	Long Term Debt Current LongTermDebtCurrent	40000
CY2023Q1	us-gaap	Employee Related Liabilities Current EmployeeRelatedLiabilitiesCurrent	1203000
CY2022Q2	us-gaap	Employee Related Liabilities Current EmployeeRelatedLiabilitiesCurrent	1520000
CY2023Q1	us-gaap	Sales And Excise Tax Payable Current SalesAndExciseTaxPayableCurrent	188000
CY2022Q2	us-gaap	Sales And Excise Tax Payable Current SalesAndExciseTaxPayableCurrent	2600000
CY2023Q1	ssy	Unearned Cares Act Funds UnearnedCARESActFunds	469000
CY2022Q2	ssy	Unearned Cares Act Funds UnearnedCARESActFunds	519000
CY2023Q1	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	351000
CY2022Q2	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	352000
CY2023Q1	us-gaap	Other Liabilities Current OtherLiabilitiesCurrent	873000
CY2022Q2	us-gaap	Other Liabilities Current OtherLiabilitiesCurrent	1313000
CY2023Q1	us-gaap	Liabilities Current LiabilitiesCurrent	4677000
CY2022Q2	us-gaap	Liabilities Current LiabilitiesCurrent	7691000
CY2023Q1	us-gaap	Long Term Debt Noncurrent LongTermDebtNoncurrent	0
CY2022Q2	us-gaap	Long Term Debt Noncurrent LongTermDebtNoncurrent	14000
CY2023Q1	ssy	Professional Liability Risks Non Current ProfessionalLiabilityRisksNonCurrent	145000
CY2022Q2	ssy	Professional Liability Risks Non Current ProfessionalLiabilityRisksNonCurrent	86000
CY2023Q1	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	612000
CY2022Q2	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	857000
CY2023Q1	us-gaap	Other Liabilities Noncurrent OtherLiabilitiesNoncurrent	197000
CY2022Q2	us-gaap	Other Liabilities Noncurrent OtherLiabilitiesNoncurrent	175000
CY2023Q1	us-gaap	Liabilities Noncurrent LiabilitiesNoncurrent	954000
CY2022Q2	us-gaap	Liabilities Noncurrent LiabilitiesNoncurrent	1132000
CY2023Q1	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	2000000
CY2022Q2	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	2000000
CY2023Q1	us-gaap	Preferred Stock Share Subscriptions PreferredStockShareSubscriptions	2000000
CY2022Q2	us-gaap	Preferred Stock Share Subscriptions PreferredStockShareSubscriptions	2000000
CY2023Q1	us-gaap	Preferred Stock Value PreferredStockValue	0
CY2022Q2	us-gaap	Preferred Stock Value PreferredStockValue	0
CY2023Q1	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	7032000
CY2023Q1	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	7032000
CY2022Q2	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	6954000
CY2022Q2	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	6954000
CY2023Q1	us-gaap	Common Stock Value CommonStockValue	3516000
CY2022Q2	us-gaap	Common Stock Value CommonStockValue	3478000
CY2023Q1	us-gaap	Additional Paid In Capital Common Stock AdditionalPaidInCapitalCommonStock	10746000
CY2022Q2	us-gaap	Additional Paid In Capital Common Stock AdditionalPaidInCapitalCommonStock	10736000
CY2023Q1	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	4431000
CY2022Q2	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	4800000
CY2023Q1	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	106000
CY2022Q2	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	106000
CY2023Q1	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	18799000
CY2022Q2	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	19120000
CY2023Q1	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	24430000
CY2022Q2	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	27943000
CY2023Q1	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	11533000
CY2022Q1	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	10527000
	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	36962000
	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	31463000
CY2023Q1	us-gaap	Labor And Related Expense LaborAndRelatedExpense	4519000
CY2022Q1	us-gaap	Labor And Related Expense LaborAndRelatedExpense	4736000
	us-gaap	Labor And Related Expense LaborAndRelatedExpense	14516000
	us-gaap	Labor And Related Expense LaborAndRelatedExpense	14223000
CY2023Q1	us-gaap	Supplies Expense SuppliesExpense	276000
CY2022Q1	us-gaap	Supplies Expense SuppliesExpense	271000
	us-gaap	Supplies Expense SuppliesExpense	1014000
	us-gaap	Supplies Expense SuppliesExpense	879000
CY2023Q1	us-gaap	Other Cost And Expense Operating OtherCostAndExpenseOperating	1171000
CY2022Q1	us-gaap	Other Cost And Expense Operating OtherCostAndExpenseOperating	1027000
	us-gaap	Other Cost And Expense Operating OtherCostAndExpenseOperating	3518000
	us-gaap	Other Cost And Expense Operating OtherCostAndExpenseOperating	3210000
CY2023Q1	us-gaap	Operating Lease Expense OperatingLeaseExpense	137000
CY2022Q1	us-gaap	Operating Lease Expense OperatingLeaseExpense	129000
	us-gaap	Operating Lease Expense OperatingLeaseExpense	381000
	us-gaap	Operating Lease Expense OperatingLeaseExpense	419000
CY2023Q1	us-gaap	Depreciation And Amortization DepreciationAndAmortization	414000
CY2022Q1	us-gaap	Depreciation And Amortization DepreciationAndAmortization	384000
	us-gaap	Depreciation And Amortization DepreciationAndAmortization	1169000
	us-gaap	Depreciation And Amortization DepreciationAndAmortization	1083000
CY2023Q1	us-gaap	Operating Income Loss OperatingIncomeLoss	-774000
CY2022Q1	us-gaap	Operating Income Loss OperatingIncomeLoss	-1064000
	us-gaap	Operating Income Loss OperatingIncomeLoss	-347000
	us-gaap	Operating Income Loss OperatingIncomeLoss	-3129000
CY2023Q1	us-gaap	Gains Losses On Sales Of Assets GainsLossesOnSalesOfAssets	0
CY2022Q1	us-gaap	Gains Losses On Sales Of Assets GainsLossesOnSalesOfAssets	0
	us-gaap	Gains Losses On Sales Of Assets GainsLossesOnSalesOfAssets	14000
	us-gaap	Gains Losses On Sales Of Assets GainsLossesOnSalesOfAssets	12000
CY2023Q1	ssy	Forgiveness Of Ppp Loans And Accrued Interest ForgivenessOfPPPLoansAndAccruedInterest	0
CY2022Q1	ssy	Forgiveness Of Ppp Loans And Accrued Interest ForgivenessOfPPPLoansAndAccruedInterest	0
	ssy	Forgiveness Of Ppp Loans And Accrued Interest ForgivenessOfPPPLoansAndAccruedInterest	0
	ssy	Forgiveness Of Ppp Loans And Accrued Interest ForgivenessOfPPPLoansAndAccruedInterest	3010000
CY2023Q1	ssy	Federal Stimulus Provider Relief Funds FederalStimulusProviderReliefFunds	0
CY2022Q1	ssy	Federal Stimulus Provider Relief Funds FederalStimulusProviderReliefFunds	106000
	ssy	Federal Stimulus Provider Relief Funds FederalStimulusProviderReliefFunds	61000
	ssy	Federal Stimulus Provider Relief Funds FederalStimulusProviderReliefFunds	720000
CY2023Q1	us-gaap	Interest Income Expense Net InterestIncomeExpenseNet	41000
CY2022Q1	us-gaap	Interest Income Expense Net InterestIncomeExpenseNet	-1000
	us-gaap	Interest Income Expense Net InterestIncomeExpenseNet	46000
	us-gaap	Interest Income Expense Net InterestIncomeExpenseNet	-18000
CY2023Q1	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-733000
CY2022Q1	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-959000
	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-226000
	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	595000
CY2023Q1	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	-6000
CY2022Q1	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	-25000
	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	-7000
	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	0
CY2023Q1	us-gaap	Income Loss From Continuing Operations IncomeLossFromContinuingOperations	-727000
CY2022Q1	us-gaap	Income Loss From Continuing Operations IncomeLossFromContinuingOperations	-934000
	us-gaap	Income Loss From Continuing Operations IncomeLossFromContinuingOperations	-219000
	us-gaap	Income Loss From Continuing Operations IncomeLossFromContinuingOperations	595000
CY2023Q1	us-gaap	Income Loss From Discontinued Operations Net Of Tax Attributable To Reporting Entity IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity	-35000
CY2022Q1	us-gaap	Income Loss From Discontinued Operations Net Of Tax Attributable To Reporting Entity IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity	-56000
	us-gaap	Income Loss From Discontinued Operations Net Of Tax Attributable To Reporting Entity IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity	-150000
	us-gaap	Income Loss From Discontinued Operations Net Of Tax Attributable To Reporting Entity IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity	-239000
CY2023Q1	us-gaap	Net Income Loss NetIncomeLoss	-762000
CY2022Q1	us-gaap	Net Income Loss NetIncomeLoss	-990000
	us-gaap	Net Income Loss NetIncomeLoss	-369000
	us-gaap	Net Income Loss NetIncomeLoss	356000
CY2023Q1	us-gaap	Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent	0
CY2022Q1	us-gaap	Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent	0
	us-gaap	Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent	0
	us-gaap	Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent	0
CY2023Q1	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-762000
CY2022Q1	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-990000
	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-369000
	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	356000
CY2023Q1	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.10
CY2022Q1	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.13
	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.03
	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	0.09
CY2023Q1	us-gaap	Income Loss From Continuing Operations Per Diluted Share IncomeLossFromContinuingOperationsPerDilutedShare	-0.10
CY2022Q1	us-gaap	Income Loss From Continuing Operations Per Diluted Share IncomeLossFromContinuingOperationsPerDilutedShare	-0.13
	us-gaap	Income Loss From Continuing Operations Per Diluted Share IncomeLossFromContinuingOperationsPerDilutedShare	-0.03
	us-gaap	Income Loss From Continuing Operations Per Diluted Share IncomeLossFromContinuingOperationsPerDilutedShare	0.08
CY2023Q1	us-gaap	Income Loss From Discontinued Operations Net Of Tax Per Basic Share IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare	-0.00
CY2022Q1	us-gaap	Income Loss From Discontinued Operations Net Of Tax Per Basic Share IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare	-0.01
	us-gaap	Income Loss From Discontinued Operations Net Of Tax Per Basic Share IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare	-0.02
	us-gaap	Income Loss From Discontinued Operations Net Of Tax Per Basic Share IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare	-0.03
CY2023Q1	us-gaap	Income Loss From Discontinued Operations Net Of Tax Per Diluted Share IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare	-0.00
CY2022Q1	us-gaap	Income Loss From Discontinued Operations Net Of Tax Per Diluted Share IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare	-0.01
	us-gaap	Income Loss From Discontinued Operations Net Of Tax Per Diluted Share IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare	-0.02
	us-gaap	Income Loss From Discontinued Operations Net Of Tax Per Diluted Share IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare	-0.03
CY2023Q1	us-gaap	Income Loss From Continuing Operations Per Basic Share IncomeLossFromContinuingOperationsPerBasicShare	-0.11
CY2022Q1	us-gaap	Income Loss From Continuing Operations Per Basic Share IncomeLossFromContinuingOperationsPerBasicShare	-0.14
	us-gaap	Income Loss From Continuing Operations Per Basic Share IncomeLossFromContinuingOperationsPerBasicShare	-0.05
	us-gaap	Income Loss From Continuing Operations Per Basic Share IncomeLossFromContinuingOperationsPerBasicShare	0.05
CY2023Q1	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.11
CY2022Q1	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.14
	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.05
	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	0.05
CY2023Q1	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	7032000
CY2022Q1	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	6954000
	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	7015000
	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	6942000
CY2023Q1	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	7032000
CY2022Q1	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	6954000
	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	7015000
	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	7063000
CY2022Q2	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	19120000
CY2022Q3	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	48000
CY2022Q3	us-gaap	Net Income Loss NetIncomeLoss	-1558000
CY2022Q3	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	17610000
CY2022Q4	us-gaap	Net Income Loss NetIncomeLoss	1951000
CY2022Q4	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	19561000
CY2023Q1	us-gaap	Net Income Loss NetIncomeLoss	-762000
CY2023Q1	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	18799000
CY2021Q2	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	20810000
CY2021Q3	us-gaap	Net Income Loss NetIncomeLoss	1939000
CY2021Q3	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	22749000
CY2021Q4	us-gaap	Net Income Loss NetIncomeLoss	-593000
CY2021Q4	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	51000
CY2021Q4	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	22207000
CY2022Q1	us-gaap	Net Income Loss NetIncomeLoss	-990000
CY2022Q1	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	21217000
	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-119000
	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-368000
	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	1525000
	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	2436000
	us-gaap	Proceeds From Sale Of Other Assets Investing Activities ProceedsFromSaleOfOtherAssetsInvestingActivities	213000
	us-gaap	Proceeds From Sale Of Other Assets Investing Activities ProceedsFromSaleOfOtherAssetsInvestingActivities	11000
	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-1312000
	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-2425000
	ssy	Proceeds From Share Option Exercises ProceedsFromShareOptionExercises	49000
	ssy	Proceeds From Share Option Exercises ProceedsFromShareOptionExercises	0
	us-gaap	Repayments Of Long Term Debt RepaymentsOfLongTermDebt	30000
	us-gaap	Repayments Of Long Term Debt RepaymentsOfLongTermDebt	25000
	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	19000
	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	-25000
	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Excluding Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect	-1412000
	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Excluding Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect	-2818000
CY2022Q2	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	6794000
CY2021Q2	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	9962000
CY2023Q1	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	5382000
CY2022Q1	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	7144000
	ssy	Interest Paid Received Net InterestPaidReceivedNet	-46000
	ssy	Interest Paid Received Net InterestPaidReceivedNet	8000
	us-gaap	Income Taxes Paid Net IncomeTaxesPaidNet	-32000
	us-gaap	Income Taxes Paid Net IncomeTaxesPaidNet	2000
	ssy	Right Of Use Asset Obtained In Exchange For Lease Liability RightOfUseAssetObtainedInExchangeForLeaseLiability	24000
	ssy	Right Of Use Asset Obtained In Exchange For Lease Liability RightOfUseAssetObtainedInExchangeForLeaseLiability	324000
	us-gaap	Nature Of Operations NatureOfOperations	<p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:"Times New Roman", serif;min-width:fit-content;">Note 2. – Business Operations</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:"Times New Roman", serif;min-width:fit-content;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:"Times New Roman", serif;min-width:fit-content;">Healthcare Services</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:"Times New Roman", serif;min-width:fit-content;">The Health Services segment includes the following:</span></p><div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:"Times New Roman", serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">•</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:"Times New Roman", serif;min-width:fit-content;">A subsidiary which owns and operates Trace Regional Medical Center (“Trace”) located in Houston, Mississippi which is composed of a </span><span style="font-size:10.0pt;font-family:"Times New Roman", serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:"Times New Roman", serif;min-width:fit-content;">49</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:"Times New Roman", serif;min-width:fit-content;"> licensed-bed acute care hospital. Our Medical Center includes a </span><span style="font-size:10.0pt;font-family:"Times New Roman", serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:"Times New Roman", serif;min-width:fit-content;">26</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:"Times New Roman", serif;min-width:fit-content;">-bed geriatric psychology unit (“GPU”), two clinics and an attached </span><span style="font-size:10.0pt;font-family:"Times New Roman", serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:"Times New Roman", serif;min-width:fit-content;">66</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:"Times New Roman", serif;min-width:fit-content;">-bed extended care and rehabilitation center. This facility focuses primarily on senior healthcare services. </span></div></div><div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:"Times New Roman", serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">•</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:"Times New Roman", serif;min-width:fit-content;">A subsidiary, SunLink Health Systems Technology (“SHS Technology”), which provides information technology ("IT”) services to outside customers and to SunLink subsidiaries.</span></div></div><div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:"Times New Roman", serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">•</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:"Times New Roman", serif;min-width:fit-content;">A subsidiary which owns approximately </span><span style="font-size:10.0pt;font-family:"Times New Roman", serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:"Times New Roman", serif;min-width:fit-content;">five</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:"Times New Roman", serif;min-width:fit-content;"> (5) acres of unimproved land in Houston, Mississippi, and </span></div></div><div style="margin-left:4.537%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:"Times New Roman", serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.491405046981553%;">•</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:"Times New Roman", serif;min-width:fit-content;"> A subsidiary which owns approximately twenty-five (</span><span style="font-size:10.0pt;font-family:"Times New Roman", serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:"Times New Roman", serif;min-width:fit-content;">25</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:"Times New Roman", serif;min-width:fit-content;">) acres of unimproved land in Ellijay, Georgia.</span></div></div><p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:"Times New Roman", serif;min-width:fit-content;">Pharmacy</span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:"Times New Roman", serif;min-width:fit-content;">The Pharmacy segment is composed of </span><span style="font-size:10.0pt;font-family:"Times New Roman", serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:"Times New Roman", serif;min-width:fit-content;">three</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:"Times New Roman", serif;min-width:fit-content;"> operational areas:</span></p><div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:"Times New Roman", serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">•</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:"Times New Roman", serif;min-width:fit-content;">Retail pharmacy products and services, consisting of retail pharmacy sales conducted in rural markets at two locations in Louisiana. This also includes non-institutional pharmacy services consisting of the provision of specialty and non-specialty pharmaceutical and biological products to clients or patients in non-institutional settings, including private residences in Louisiana; </span></div></div><div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:"Times New Roman", serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">•</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:"Times New Roman", serif;min-width:fit-content;">Institutional pharmacy services consisting of the provision of specialty and non-specialty pharmaceutical and biological products to institutional clients or to patients in institutional settings, such as extended care and rehabilitation centers, nursing homes, assisted living facilities, behavioral and specialty hospitals, hospice, and correctional facilities; and,</span></div></div><div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:"Times New Roman", serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">•</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:"Times New Roman", serif;min-width:fit-content;">Durable medical equipment products and services (“DME”), consisting primarily of the sale and rental of products for institutional clients or to patients in institutional settings and patient-administered home care.</span></div></div><p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(33,37,41,1);white-space:pre-wrap;font-weight:bold;text-decoration:underline;font-size:10.0pt;font-family:"Times New Roman", serif;min-width:fit-content;">COVID-19 Pandemic and CARES Act Funding</span></p><p style="text-indent:4.173%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(33,37,41,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:"Times New Roman", serif;min-width:fit-content;">COVID-19 was declared a global pandemic by the World Health Organization on March 11, 2020. We believe the effect of the COVID-19 pandemic and its aftermath and certain of the public and certain governmental responses to it have in varying degrees negatively affected each of our last thirteen quarter’s results.</span><span style="color:rgba(33,37,41,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:"Times New Roman", serif;min-width:fit-content;"> </span></p><p style="text-indent:4.173%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:"Times New Roman", serif;min-width:fit-content;"> </span></p><p style="text-indent:4.173%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(33,37,41,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:"Times New Roman", serif;min-width:fit-content;">During the pandemic and its aftermath our Healthcare business experienced material reductions in demand and net revenues. Shortages of and increased cost of certain medical supplies and equipment related to the COVID-19 pandemic as well as increases in the levels of salaries, wages and benefits, have continued adversely to affect our Healthcare businesses. In addition, we experienced loss of some employees, including clinical staff, believed due to, among other things, federally mandated vaccination of healthcare workers against COVID-19.</span><span style="color:rgba(33,37,41,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:"Times New Roman", serif;min-width:fit-content;"> </span></p><p style="text-indent:4.173%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:"Times New Roman", serif;min-width:fit-content;"> </span></p><p style="text-indent:4.173%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:"Times New Roman", serif;min-width:fit-content;">Our Pharmacy business has also experienced reduced sales trends in certain areas, increased costs and reduced staff due to </span><span style="background-color:rgba(0,0,0,0);color:rgba(33,37,41,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:"Times New Roman", serif;min-width:fit-content;">the COVID-19 pandemic and its aftermath as well as material reductions in demand and net revenues</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:"Times New Roman", serif;min-width:fit-content;">. Many of our primary physician referral sources operated at reduced capacity, and not all have resumed operating at full capacity. We believe the COVID-19 pandemic and its aftermath continues negatively to affect the cost of, and result in a lack of, inventory for, certain DME products and Retail and Institutional Pharmacy drugs and products. Our Institutional Pharmacy services also experienced increased costs and operational inefficiencies due to measures taken by us and restrictions implemented by our institutional customers in response to the COVID-19 pandemic and its aftermath.</span></p><p style="margin-left:0.32%;text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;margin-right:0.324%;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:"Times New Roman", serif;min-width:fit-content;"> </span></p><p style="margin-left:0.32%;text-indent:6.307%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;margin-right:0.324%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:"Times New Roman", serif;min-width:fit-content;">Our Healthcare and Pharmacy segments have received approximately $</span><span style="font-size:10.0pt;font-family:"Times New Roman", serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:"Times New Roman", serif;min-width:fit-content;">6,182</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:"Times New Roman", serif;min-width:fit-content;"> in general and targeted Provider Relief Funds ("PRF") during the period April 1, 2020 through March 31, 2023 under the CARES Act, which was enacted in March 2020 in response to the COVID-19 pandemic. The PRF distributions have been accounted for as government grants, and a total of $</span><span style="font-size:10.0pt;font-family:"Times New Roman", serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:"Times New Roman", serif;min-width:fit-content;">5,713</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:"Times New Roman", serif;min-width:fit-content;">, have been recognized since April l, 2020 as other income under the gain contingency recognition method.</span></p><p style="margin-left:0.32%;text-indent:6.307%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;margin-right:0.324%;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:"Times New Roman", serif;min-width:fit-content;"> </span></p><p style="margin-left:0.32%;text-indent:6.307%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;margin-right:0.324%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:"Times New Roman", serif;min-width:fit-content;">During the quarter ended June 30, 2020, our Healthcare and Pharmacy segments received $</span><span style="font-size:10.0pt;font-family:"Times New Roman", serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:"Times New Roman", serif;min-width:fit-content;">3,234</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:"Times New Roman", serif;min-width:fit-content;"> in Paycheck Protection Plan (“PPP”) loans provided under the CARES Act. These loans were forgivable upon compliance with conditions specified under the PPP loan program. As of March 31, 2023, all our PPP loans have been forgiven.</span></p><p style="margin-left:0.32%;text-indent:6.307%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;margin-right:0.324%;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:"Times New Roman", serif;min-width:fit-content;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:"Times New Roman", serif;min-width:fit-content;"> The Taxpayer Certainty and Disaster Tax Relief Act of 2020, enacted December 27, 2020, made a number of changes to employer retention tax credits previously made available under the CARES Act, including modifying and extending the Employee Retention Credit ("ERC") for the six calendar months ending June 30, 2021. As a result of such legislation, the Company qualified for ERC for the first and second calendar quarters of 2021 due to the decrease in its gross receipts and has applied for ERC of $</span><span style="font-size:10.0pt;font-family:"Times New Roman", serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:"Times New Roman", serif;min-width:fit-content;">3,586</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:"Times New Roman", serif;min-width:fit-content;"> through amended quarterly payroll tax filings for the applicable quarters. Through the date of this filing, the Company has received all of the ERC which we applied for. We continue to monitor compliance with the terms and conditions of the ERC and PPP programs and developing interpretations and enforcement of the ERC and PPP program rules and regulations.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:"Times New Roman", serif;min-width:fit-content;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(27,27,27,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:"Times New Roman", serif;min-width:fit-content;"> </span></p><p style="margin-left:0.32%;text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:12.0pt;margin-right:0.324%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:"Times New Roman", serif;min-width:fit-content;"> PRF distributions, PPP loan forgiveness and other grants received during the pandemic are subject to Federal audits and Single Audits and not subject to repayment provided we are able to attest to and comply with the terms and conditions of the funding, including demonstrating that the funds received have been used for designated, allowable healthcare-related expenses and capital expenditures attributable to COVID-19 and for "Lost Revenues" as defined by the department of “HHS”. We continue to monitor compliance with the terms and conditions such funds received, as well as the impact of the pandemic on our revenues and expenses. If we are unable to attest to or comply with current or future terms and conditions, and there is no assurance we will continue to be able to do so,</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:"Times New Roman", serif;min-width:fit-content;"> </span></p><p style="margin-left:0.32%;text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:12.0pt;margin-right:0.324%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:"Times New Roman", serif;min-width:fit-content;">our ability to retain some or all of the PRF and other grants received may be impacted, and we may have to return the unutilized portion of those funds, if any, in the future. The Company filed its Schedule of Grant Income of HHS awards and audit report for the year ended June 30, 2021 with the Health Resources and Services Administration (“HRSA”) agency of HHS on September 30, 2022.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:"Times New Roman", serif;min-width:fit-content;"> </span></p><p style="margin-left:0.32%;text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:12.0pt;margin-right:0.324%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:"Times New Roman", serif;min-width:fit-content;"> </span></p>
	ssy	Employee Retention Credit Amending Quarterly Payroll Tax Filing Amount EmployeeRetentionCreditAmendingQuarterlyPayrollTaxFilingAmount	3586000
CY2023Q1	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	0
	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	0
CY2022Q1	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	0
	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	0
CY2023Q1	us-gaap	Stock Issued During Period Shares Stock Options Exercised StockIssuedDuringPeriodSharesStockOptionsExercised	77452
CY2023Q1	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	11533000
CY2022Q1	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	10527000
	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	36962000
	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	31463000
CY2023Q1	ssy	Health Care Organization Significant Change In Estimates HealthCareOrganizationSignificantChangeInEstimates	151000
	ssy	Health Care Organization Significant Change In Estimates HealthCareOrganizationSignificantChangeInEstimates	151000
CY2022Q1	ssy	Health Care Organization Significant Change In Estimates HealthCareOrganizationSignificantChangeInEstimates	186000
	ssy	Health Care Organization Significant Change In Estimates HealthCareOrganizationSignificantChangeInEstimates	186000
	ssy	Reversed Accrued Sales Tax ReversedAccruedSalesTax	2615000
	us-gaap	Operating Lease Cost OperatingLeaseCost	362000
CY2023Q1	ssy	Short Term Lease Cost Income ShortTermLeaseCostIncome	52000
CY2022Q1	ssy	Short Term Lease Cost Income ShortTermLeaseCostIncome	17000
	ssy	Short Term Lease Cost Income ShortTermLeaseCostIncome	113000
	ssy	Short Term Lease Cost Income ShortTermLeaseCostIncome	56000
CY2023Q1	ssy	Operating Variable Lease Cost OperatingVariableLeaseCost	0
CY2022Q1	ssy	Operating Variable Lease Cost OperatingVariableLeaseCost	0
	ssy	Operating Variable Lease Cost OperatingVariableLeaseCost	2000
CY2023Q1	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	6000
CY2022Q1	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	7000
	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	19000
	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	20000
CY2023Q1	ssy	Finance Lease Obligations FinanceLeaseObligations	24000
CY2022Q2	ssy	Finance Lease Obligations FinanceLeaseObligations	54000
CY2023Q1	us-gaap	Long Term Debt And Capital Lease Obligations Current LongTermDebtAndCapitalLeaseObligationsCurrent	24000
CY2022Q2	us-gaap	Long Term Debt And Capital Lease Obligations Current LongTermDebtAndCapitalLeaseObligationsCurrent	40000
CY2023Q1	us-gaap	Long Term Debt And Capital Lease Obligations LongTermDebtAndCapitalLeaseObligations	0
CY2022Q2	us-gaap	Long Term Debt And Capital Lease Obligations LongTermDebtAndCapitalLeaseObligations	14000
CY2023Q1	us-gaap	Current State And Local Tax Expense Benefit CurrentStateAndLocalTaxExpenseBenefit	6000
CY2022Q1	us-gaap	Current State And Local Tax Expense Benefit CurrentStateAndLocalTaxExpenseBenefit	25000
	us-gaap	Current State And Local Tax Expense Benefit CurrentStateAndLocalTaxExpenseBenefit	7000
	us-gaap	Current State And Local Tax Expense Benefit CurrentStateAndLocalTaxExpenseBenefit	0
CY2023Q1	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance	7906000
CY2023Q1	us-gaap	Deferred Tax Assets Net DeferredTaxAssetsNet	0
CY2023Q1	us-gaap	Deferred Tax Liabilities DeferredTaxLiabilities	69000
CY2023Q1	us-gaap	Operating Loss Carryforwards OperatingLossCarryforwards	22784000
CY2023Q1	us-gaap	Operating Loss Carryforwards OperatingLossCarryforwards	22784000
	ssy	Net Operating Loss Carry Forwards Expire Period NetOperatingLossCarryForwardsExpirePeriod	2023 through fiscal year 2038
CY2023Q1	us-gaap	Operating Lease Cost OperatingLeaseCost	85000
CY2022Q1	us-gaap	Operating Lease Cost OperatingLeaseCost	112000
	us-gaap	Operating Lease Cost OperatingLeaseCost	266000
	ssy	Operating Variable Lease Cost OperatingVariableLeaseCost	1000
CY2023Q1	us-gaap	Operating Lease Expense OperatingLeaseExpense	137000
CY2022Q1	us-gaap	Operating Lease Expense OperatingLeaseExpense	129000
	us-gaap	Operating Lease Expense OperatingLeaseExpense	381000
	us-gaap	Operating Lease Expense OperatingLeaseExpense	419000
CY2023Q1	us-gaap	Finance Lease Right Of Use Asset Amortization FinanceLeaseRightOfUseAssetAmortization	11000
CY2022Q1	us-gaap	Finance Lease Right Of Use Asset Amortization FinanceLeaseRightOfUseAssetAmortization	9000
	us-gaap	Finance Lease Right Of Use Asset Amortization FinanceLeaseRightOfUseAssetAmortization	29000
	us-gaap	Finance Lease Right Of Use Asset Amortization FinanceLeaseRightOfUseAssetAmortization	27000
CY2023Q1	us-gaap	Finance Lease Interest Expense FinanceLeaseInterestExpense	0
CY2022Q1	us-gaap	Finance Lease Interest Expense FinanceLeaseInterestExpense	1000
	us-gaap	Finance Lease Interest Expense FinanceLeaseInterestExpense	2000
	us-gaap	Finance Lease Interest Expense FinanceLeaseInterestExpense	4000
CY2023Q1	ssy	Finance Lease Cost FinanceLeaseCost	11000
CY2022Q1	ssy	Finance Lease Cost FinanceLeaseCost	10000
	ssy	Finance Lease Cost FinanceLeaseCost	31000
	ssy	Finance Lease Cost FinanceLeaseCost	31000
CY2023Q1	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	947000
CY2022Q2	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	1187000
CY2023Q1	us-gaap	Finance Lease Right Of Use Asset FinanceLeaseRightOfUseAsset	203000
CY2022Q2	us-gaap	Finance Lease Right Of Use Asset FinanceLeaseRightOfUseAsset	203000
CY2023Q1	us-gaap	Property Plant And Equipment Owned Accumulated Depreciation PropertyPlantAndEquipmentOwnedAccumulatedDepreciation	125000
CY2022Q2	us-gaap	Property Plant And Equipment Owned Accumulated Depreciation PropertyPlantAndEquipmentOwnedAccumulatedDepreciation	101000
CY2023Q1	us-gaap	Finance Lease Liability Current FinanceLeaseLiabilityCurrent	24000
CY2022Q2	us-gaap	Finance Lease Liability Current FinanceLeaseLiabilityCurrent	40000
CY2023Q1	us-gaap	Finance Lease Liability Noncurrent FinanceLeaseLiabilityNoncurrent	0
CY2022Q2	us-gaap	Finance Lease Liability Noncurrent FinanceLeaseLiabilityNoncurrent	14000
CY2023Q1	us-gaap	Operating Lease Payments OperatingLeasePayments	91000
CY2022Q1	us-gaap	Operating Lease Payments OperatingLeasePayments	114000
	us-gaap	Operating Lease Payments OperatingLeasePayments	273000
	us-gaap	Operating Lease Payments OperatingLeasePayments	366000
CY2023Q1	ssy	Operating Cash Flows From Finance Lease OperatingCashFlowsFromFinanceLease	2000
CY2022Q1	ssy	Operating Cash Flows From Finance Lease OperatingCashFlowsFromFinanceLease	1000
	ssy	Operating Cash Flows From Finance Lease OperatingCashFlowsFromFinanceLease	2000
	ssy	Operating Cash Flows From Finance Lease OperatingCashFlowsFromFinanceLease	4000
CY2023Q1	us-gaap	Finance Lease Principal Payments FinanceLeasePrincipalPayments	10000
CY2022Q1	us-gaap	Finance Lease Principal Payments FinanceLeasePrincipalPayments	10000
	us-gaap	Finance Lease Principal Payments FinanceLeasePrincipalPayments	29000
	us-gaap	Finance Lease Principal Payments FinanceLeasePrincipalPayments	28000
CY2023Q1	us-gaap	Right Of Use Asset Obtained In Exchange For Operating Lease Liability RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability	0
CY2022Q1	us-gaap	Right Of Use Asset Obtained In Exchange For Operating Lease Liability RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability	289000
	us-gaap	Right Of Use Asset Obtained In Exchange For Operating Lease Liability RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability	24000
	us-gaap	Right Of Use Asset Obtained In Exchange For Operating Lease Liability RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability	324000
CY2023Q1	us-gaap	Operating Lease Weighted Average Remaining Lease Term1 OperatingLeaseWeightedAverageRemainingLeaseTerm1	P2Y9M29D
CY2022Q1	us-gaap	Operating Lease Weighted Average Remaining Lease Term1 OperatingLeaseWeightedAverageRemainingLeaseTerm1	P3Y8M26D
CY2023Q1	us-gaap	Operating Lease Weighted Average Remaining Lease Term1 OperatingLeaseWeightedAverageRemainingLeaseTerm1	P2Y9M29D
CY2022Q1	us-gaap	Operating Lease Weighted Average Remaining Lease Term1 OperatingLeaseWeightedAverageRemainingLeaseTerm1	P3Y8M26D
CY2023Q1	us-gaap	Finance Lease Weighted Average Remaining Lease Term1 FinanceLeaseWeightedAverageRemainingLeaseTerm1	P0Y7M28D
CY2022Q1	us-gaap	Finance Lease Weighted Average Remaining Lease Term1 FinanceLeaseWeightedAverageRemainingLeaseTerm1	P1Y7M28D
CY2023Q1	us-gaap	Finance Lease Weighted Average Remaining Lease Term1 FinanceLeaseWeightedAverageRemainingLeaseTerm1	P0Y7M28D
CY2022Q1	us-gaap	Finance Lease Weighted Average Remaining Lease Term1 FinanceLeaseWeightedAverageRemainingLeaseTerm1	P1Y7M28D
CY2023Q1	us-gaap	Operating Lease Weighted Average Discount Rate Percent OperatingLeaseWeightedAverageDiscountRatePercent	0.0100
CY2022Q1	us-gaap	Operating Lease Weighted Average Discount Rate Percent OperatingLeaseWeightedAverageDiscountRatePercent	0.0104
CY2023Q1	us-gaap	Operating Lease Weighted Average Discount Rate Percent OperatingLeaseWeightedAverageDiscountRatePercent	0.0100
CY2022Q1	us-gaap	Operating Lease Weighted Average Discount Rate Percent OperatingLeaseWeightedAverageDiscountRatePercent	0.0104
CY2023Q1	us-gaap	Finance Lease Weighted Average Discount Rate Percent FinanceLeaseWeightedAverageDiscountRatePercent	0.0654
CY2022Q1	us-gaap	Finance Lease Weighted Average Discount Rate Percent FinanceLeaseWeightedAverageDiscountRatePercent	0.0654
CY2023Q1	us-gaap	Finance Lease Weighted Average Discount Rate Percent FinanceLeaseWeightedAverageDiscountRatePercent	0.0654
CY2022Q1	us-gaap	Finance Lease Weighted Average Discount Rate Percent FinanceLeaseWeightedAverageDiscountRatePercent	0.0654
CY2023Q1	us-gaap	Lessee Operating Lease Liability Payments Remainder Of Fiscal Year LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear	359000
CY2023Q1	us-gaap	Finance Lease Liability Payments Remainder Of Fiscal Year FinanceLeaseLiabilityPaymentsRemainderOfFiscalYear	25000
CY2023Q1	us-gaap	Lessee Operating Lease Liability Payments Due Next Twelve Months LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths	342000
CY2023Q1	us-gaap	Finance Lease Liability Payments Due Next Twelve Months FinanceLeaseLiabilityPaymentsDueNextTwelveMonths	0
CY2023Q1	us-gaap	Lessee Operating Lease Liability Payments Due Year Two LesseeOperatingLeaseLiabilityPaymentsDueYearTwo	255000
CY2023Q1	us-gaap	Finance Lease Liability Payments Due Year Two FinanceLeaseLiabilityPaymentsDueYearTwo	0
CY2023Q1	us-gaap	Lessee Operating Lease Liability Payments Due Year Three LesseeOperatingLeaseLiabilityPaymentsDueYearThree	16000
CY2023Q1	us-gaap	Finance Lease Liability Payments Due Year Three FinanceLeaseLiabilityPaymentsDueYearThree	0
CY2023Q1	us-gaap	Lessee Operating Lease Liability Payments Due Year Four LesseeOperatingLeaseLiabilityPaymentsDueYearFour	5000
CY2023Q1	us-gaap	Finance Lease Liability Payments Due Year Four FinanceLeaseLiabilityPaymentsDueYearFour	0
CY2023Q1	ssy	Lessee Operating Lease Liability Payments Due After Year Four LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFour	0
CY2023Q1	ssy	Finance Lease Liability Payments Due After Year Four FinanceLeaseLiabilityPaymentsDueAfterYearFour	0
CY2023Q1	us-gaap	Lessee Operating Lease Liability Payments Due LesseeOperatingLeaseLiabilityPaymentsDue	977000
CY2023Q1	us-gaap	Finance Lease Liability Payments Due FinanceLeaseLiabilityPaymentsDue	25000
CY2023Q1	us-gaap	Lessee Operating Lease Liability Undiscounted Excess Amount LesseeOperatingLeaseLiabilityUndiscountedExcessAmount	14000
CY2023Q1	us-gaap	Finance Lease Liability Undiscounted Excess Amount FinanceLeaseLiabilityUndiscountedExcessAmount	1000
CY2023Q1	us-gaap	Operating Lease Liability OperatingLeaseLiability	963000
CY2023Q1	us-gaap	Finance Lease Liability FinanceLeaseLiability	24000
CY2023Q1	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	351000
CY2023Q1	us-gaap	Finance Lease Liability Current FinanceLeaseLiabilityCurrent	24000
CY2023Q1	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	612000
CY2023Q1	us-gaap	Finance Lease Liability Noncurrent FinanceLeaseLiabilityNoncurrent	0
	ssy	Number Of Taxing Authorities NumberOfTaxingAuthorities	2
CY2020Q2	us-gaap	Income Tax Examination Liability Refund Adjustment From Settlement With Taxing Authority IncomeTaxExaminationLiabilityRefundAdjustmentFromSettlementWithTaxingAuthority	359000
CY2023Q1	us-gaap	Income Tax Examination Liability Refund Adjustment From Settlement With Taxing Authority IncomeTaxExaminationLiabilityRefundAdjustmentFromSettlementWithTaxingAuthority	1500000
CY2022Q4	ssy	Reversed Accrued Sales Tax ReversedAccruedSalesTax	2615000
	us-gaap	Number Of Reportable Segments NumberOfReportableSegments	2
CY2023Q1	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	11533000
CY2023Q1	us-gaap	Operating Income Loss OperatingIncomeLoss	-774000
CY2023Q1	us-gaap	Depreciation And Amortization DepreciationAndAmortization	414000
CY2023Q1	us-gaap	Assets Assets	24430000
CY2023Q1	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	374000
CY2022Q1	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	10527000
CY2022Q1	us-gaap	Operating Income Loss OperatingIncomeLoss	-1064000
CY2022Q1	us-gaap	Depreciation And Amortization DepreciationAndAmortization	384000
CY2022Q1	us-gaap	Assets Assets	29957000
CY2022Q1	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	918000
	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	36962000
	us-gaap	Operating Income Loss OperatingIncomeLoss	-347000
	us-gaap	Depreciation And Amortization DepreciationAndAmortization	1169000
CY2022Q4	us-gaap	Assets Assets	24430000
	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	1525000
	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	31463000
	us-gaap	Operating Income Loss OperatingIncomeLoss	-3129000
	us-gaap	Depreciation And Amortization DepreciationAndAmortization	1083000
CY2021Q4	us-gaap	Assets Assets	29957000
	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	2436000

Files In Submission

Name	View Source	Status
FilingSummary.xml	Edgar Link	unprocessable
0000950170-23-020620-index-headers.html	Edgar Link	pending
0000950170-23-020620-index.html	Edgar Link	pending
0000950170-23-020620.txt	Edgar Link	pending
0000950170-23-020620-xbrl.zip	Edgar Link	pending
Financial_Report.xlsx	Edgar Link	pending
MetaLinks.json	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
R35.htm	Edgar Link	pending
R36.htm	Edgar Link	pending
R37.htm	Edgar Link	pending
R38.htm	Edgar Link	pending
R39.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R40.htm	Edgar Link	pending
R41.htm	Edgar Link	pending
R42.htm	Edgar Link	pending
R43.htm	Edgar Link	pending
R44.htm	Edgar Link	pending
R45.htm	Edgar Link	pending
R46.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending
ssy-20230331.htm	Edgar Link	pending
ssy-20230331.xsd	Edgar Link	pending
ssy-ex31_1.htm	Edgar Link	pending
ssy-ex31_2.htm	Edgar Link	pending
ssy-ex32_1.htm	Edgar Link	pending
ssy-ex32_2.htm	Edgar Link	pending
ssy-20230331_def.xml	Edgar Link	unprocessable
ssy-20230331_lab.xml	Edgar Link	unprocessable
ssy-20230331_cal.xml	Edgar Link	unprocessable
ssy-20230331_pre.xml	Edgar Link	unprocessable
ssy-20230331_htm.xml	Edgar Link	completed

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$SSY
SUNLINK HEALTH SYSTEMS INC Stock $ssy

2023 Q2 Form 10-Q Financial Statement

#000095017023020620 Filed on May 10, 2023

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$SSY SUNLINK HEALTH SYSTEMS INC Stock $ssy

2023 Q2 Form 10-Q Financial Statement

#000095017023020620 Filed on May 10, 2023

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$SSY
SUNLINK HEALTH SYSTEMS INC Stock $ssy